Also trades as: NBRV (NASDAQ) · $vol 0M
NBRVF OTC
Nabriva Therapeutics plc
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: -0.0%
$0.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$36M
+31.1% ▲
Gross Profit
$7M
-49.6% ▼
Operating Income
-$55M
-14.3% ▼
Net Income
-$57M
-15.6% ▼
EPS (Diluted)
$-21.32
+25.2% ▲
EBITDA
-$55M
-15.4% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $6M | $8M | $5M | $27M | $36M |
| YoY Growth | +0.0% | +19.2% | -35.1% | +441.4% | +31.1% |
| Cost of Revenue | $0 | $70K | $2M | $13M | $29M |
| Gross Profit | $6M | $8M | $3M | $14M | $7M |
| Gross Margin | 100.0% | 99.1% | 68.5% | 51.7% | 19.9% |
| R&D Expenses | $82M | $26M | $15M | $13M | $14M |
| SG&A Expenses | $42M | $62M | $55M | $52M | $45M |
| Operating Expenses | $121M | $87M | $70M | $63M | $63M |
| Operating Income | -$114M | -$79M | -$66M | -$49M | -$55M |
| Operating Margin | -1759.6% | -1025.9% | -1315.4% | -178.3% | -155.6% |
| Interest Expense | $133K | $4M | $2M | $901K | $698K |
| Income Before Tax | -$115M | -$83M | -$69M | -$49M | -$56M |
| Tax Expense | $49K | $101K | $139K | $490K | $2M |
| Net Income | -$115M | -$83M | -$69M | -$49M | -$57M |
| Net Margin | -1765.8% | -1068.2% | -1382.2% | -181.7% | -160.3% |
| EPS (Diluted) | $-564.91 | $-278.75 | $-135.23 | $-28.52 | $-21.32 |
| EBITDA | -$114M | -$79M | -$67M | -$47M | -$55M |
| Shares Outstanding | 203183 | 296797 | 513804 | 2M | 3M |